SwitzerlandSwitzerland

Leukemia - BMS drug more effective than Novartis' Glivec

07.06.2010

Basel/Chicago/Princeton - Preliminay data from a Phase III study show that BistolMyers Squibb's (BMS) BCR-ABL kinase inhibitor dasatinib (Sprycel) is superior to Swiss Novartis' standard first-line therapy, imatinib (Glivec), for bringing about cytogenetic and molecular responses in patients newly diagnosed with chronic myeloid leukemia (CML). According to results presented at the ASCO meeting in Chicago, 73% of blood cancers did not progress after 3 years of treatment with Sprycel and 87% of CML patients, who do not respond to imatinib, survived. In a head-to-head comparison with Glivec, Sprycel seemed to be more effective. 77% of the patients treated with the BMS drug showed the complete disappearance of cells with the Philadelphia chromosome, a surrogate marker for long-term survival of CML patients, compared to 66% of patients treated with Glivec after 12 months of treatment. Additionally, the rate of major molecular responses – another marker of drug effectiveness – was also higher with dasatinib (46%) than imatinib (28%). Both drugs showed similar side effects such as Grade 3/4 anemia (10% vs 7%) and neutropenia (21% vs 20%). However, thrombocytopenia was more common for dasatinib (19% vs 10%). In a separate press statement, Novartis announced that 18-month results from a study confirmed its nilotinib (Tasigna) cancer drug is more efficient in slowing down CLM than older medicine Glivec, its second-biggest selling drug. The results will be also presented at the ASCO meeting.

Politics / Law

06.03.2012

London – The European Medicines Agency (EMA) calls it “the biggest change to the legal framework since the establishment of the Agency in 1995.” This year, the EU drug regulators are preparing new so-called pharmacovigilance...

Clinical Trial

06.03.2012

Norway’s Algeta ASA (Oslo) has updated its Phase III survival analysis of Alpharadin in patients with castration-resistant prostate cancer and bone metastases. The analysis showed an increase of 3.6 months in median overall...

Clinical Trial

06.03.2012

Genticel S.A. (Toulouse) has completed enrolment in its Phase Ib study of a lyophilised version of the world’s very first therapeutic vaccine ProCervix, which inhibits infection with the cancer-causing Human Papilloma Virus. The...

Clinical Trial

06.03.2012

The share value of French specialist for cardiometabolic diseases Genfit S.A. (Loos/Lille) took a jump after the company announced its candidate drug GFT505 had met all efficacy endpoints in a pilot Phase II study involving 22...

Clinical Trial

06.03.2012

The US Food and Drug Administration (FDA) has granted a Biologics License Application (BLA) to the HER2 dimerisation inhibitor pertuzumab developed by Roche (Basel) for previously untreated HER2­-positive metastatic breast...

Politics / Law

06.03.2012

A For years, the world’s major patent offices – including the EPO, USPTO and JPO – have been collaborating in the Patent Prosecution Highway (PPH) programme. Under the PPH, an applicant whose claims have been allowed in one...

BioFunding

06.03.2012

Berlin/Dublin – Two EU initiatives are seeking to better predict response to cancer treatments. Researchers from the a6m RESPONSIFY Project will develop biomarker-based breast cancer prognosis tests that could be used to predict...

BioFunding

06.03.2012

Bremen/Brussels – European researchers kicked-off the MicroB3 (Bio­diversity, Bioinformatics, Biotechnology) project in February. Thanks to a a9m EU fund, the 32 groups involved will create a unique bioinformatic resource that...

BioFunding

06.03.2012

A Brussels – The European Commission is boosting its investments and policy activities to foster sustainability. “Europe needs to make the transition to a post-petroleum economy,” said Máire Geoghegan-Quinn in Brussels. In...

Politics / Law

06.03.2012

Brussels – In February, I heard of a slightly mad and very worrying trend in decisions handed down by the Court of Justice of the European Union (CJEU) with regard to IP issues handed up from the national level for clarification....

Displaying results 11 to 20 out of 1983

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/1/article/leukemia-bms-drug-more-effective-than-novartis-glivec.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA80.00 CHF6.74%
  • WILEX2.26 EUR1.80%
  • ADDEX4.07 CHF1.75%

FLOP

  • MOLOGEN7.30 EUR-6.41%
  • 4SC1.16 EUR-3.33%
  • EVOLVA1.27 CHF-2.31%

TOP

  • SANTHERA80.00 CHF15.4%
  • MAGFORCE6.47 EUR9.7%
  • CYTOS0.27 CHF8.0%

FLOP

  • WILEX2.26 EUR-27.6%
  • MOLOGEN7.30 EUR-22.3%
  • 4SC1.16 EUR-20.0%

TOP

  • SANTHERA80.00 CHF3709.5%
  • CO.DON2.50 EUR228.9%
  • PAION2.41 EUR190.4%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-68.1%
  • MERCK KGAA64.23 EUR-45.8%

No liability assumed, Date: 21.08.2014


Current issue

All issues

Product of the week

Products